![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NRK |
Gene summary for NRK |
![]() |
Gene information | Species | Human | Gene symbol | NRK | Gene ID | 203447 |
Gene name | Nik related kinase | |
Gene Alias | NESK | |
Cytomap | Xq22.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q7Z2Y5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
203447 | NRK | ATC13 | Human | Thyroid | ATC | 1.61e-39 | 7.98e-01 | 0.34 |
203447 | NRK | ATC5 | Human | Thyroid | ATC | 1.13e-41 | 8.40e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003009912 | Liver | Cirrhotic | myeloid cell differentiation | 135/4634 | 381/18723 | 1.69e-06 | 3.22e-05 | 135 |
GO:003009922 | Liver | HCC | myeloid cell differentiation | 200/7958 | 381/18723 | 4.64e-05 | 4.49e-04 | 200 |
GO:003009928 | Skin | AK | myeloid cell differentiation | 72/1910 | 381/18723 | 1.76e-07 | 7.28e-06 | 72 |
GO:0030099112 | Skin | SCCIS | myeloid cell differentiation | 41/919 | 381/18723 | 2.11e-06 | 1.09e-04 | 41 |
GO:003009929 | Skin | cSCC | myeloid cell differentiation | 146/4864 | 381/18723 | 6.38e-08 | 1.61e-06 | 146 |
GO:0031532111 | Thyroid | ATC | actin cytoskeleton reorganization | 62/6293 | 107/18723 | 2.01e-07 | 3.17e-06 | 62 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NRK | SNV | Missense_Mutation | c.4082N>G | p.Asp1361Gly | p.D1361G | Q7Z2Y5 | protein_coding | tolerated_low_confidence(0.05) | probably_damaging(0.999) | TCGA-D7-6818-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
NRK | SNV | Missense_Mutation | c.4619A>G | p.Lys1540Arg | p.K1540R | Q7Z2Y5 | protein_coding | deleterious(0.01) | possibly_damaging(0.651) | TCGA-FP-8211-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | xeloda | CR | |
NRK | SNV | Missense_Mutation | novel | c.1398N>T | p.Lys466Asn | p.K466N | Q7Z2Y5 | protein_coding | deleterious_low_confidence(0) | benign(0.021) | TCGA-HF-A5NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
NRK | SNV | Missense_Mutation | c.4348N>C | p.Lys1450Gln | p.K1450Q | Q7Z2Y5 | protein_coding | deleterious(0.02) | benign(0.033) | TCGA-IN-8663-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
NRK | SNV | Missense_Mutation | novel | c.4468N>G | p.Phe1490Val | p.F1490V | Q7Z2Y5 | protein_coding | deleterious(0.03) | benign(0.197) | TCGA-IN-A6RO-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | irinotecan | PD |
NRK | SNV | Missense_Mutation | novel | c.2405N>C | p.Lys802Thr | p.K802T | Q7Z2Y5 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-KB-A93H-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NRK | SNV | Missense_Mutation | rs763824052 | c.694N>T | p.Arg232Cys | p.R232C | Q7Z2Y5 | protein_coding | tolerated(0.06) | benign(0.028) | TCGA-R5-A7ZI-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NRK | SNV | Missense_Mutation | novel | c.3329N>C | p.Asn1110Thr | p.N1110T | Q7Z2Y5 | protein_coding | tolerated(0.34) | benign(0) | TCGA-RD-A7BT-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
NRK | SNV | Missense_Mutation | c.3352T>G | p.Ser1118Ala | p.S1118A | Q7Z2Y5 | protein_coding | tolerated(0.3) | benign(0.021) | TCGA-VQ-A8PK-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
NRK | SNV | Missense_Mutation | novel | c.4718T>C | p.Leu1573Pro | p.L1573P | Q7Z2Y5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.963) | TCGA-VQ-A8PK-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |